MedTrace Logo

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

NCT02578121 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-01-23

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy of Ixazomib when combined with Pomalidomide and Dexamethasone, in terms of overall response rate in subjects with relapsed Multiple Myeloma

Conditions

Interventions

DRUG

Ixazomib

4.0 mg will be given on days 1, 8 and 15 of a 28 day cycle

DRUG

Pomalidomide

4.0 mg will be given on days 1-21 of a 28 day cycle

DRUG

Dexamethasone

20 mg will be given on days 1, 8, 15 and 22 of a 28 day cycle

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Faith Davies, MD · University of Arkansas

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02578121 on ClinicalTrials.gov